TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
1-Year Return
21.62%
This Quarter Return
+10.56%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$1.98B
AUM Growth
+$171M
(+9.4%)
Cap. Flow
+$118M
Cap. Flow
% of AUM
5.98%
Top 10 Holdings %
Top 10 Hldgs %
35.03%
Holding
220
New
18
Increased
34
Reduced
52
Closed
20
Top Buys
| 1 |
Vera Therapeutics
VERA
|
$28.3M |
| 2 |
Merus
MRUS
|
$26.3M |
| 3 |
Mettler-Toledo International
MTD
|
$22.9M |
| 4 |
Boeing
BA
|
$20.9M |
| 5 |
Spyre Therapeutics
SYRE
|
$17.2M |
Top Sells
| 1 |
Dynavax Technologies
DVAX
|
$37.7M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$29M |
| 3 |
SLRN
ACELYRIN
SLRN
|
$24.3M |
| 4 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$10.1M |
| 5 |
CRISPR Therapeutics
CRSP
|
$9.07M |
Sector Composition
| 1 | Healthcare | 94.16% |
| 2 | Technology | 1.37% |
| 3 | Industrials | 1.32% |
| 4 | Communication Services | 1.26% |
| 5 | Consumer Discretionary | 0.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Arvinas
ARVN
$559M
| $10.3M | 0.52% |
1,393,800
| – | – |
|
52
Viking Therapeutics
VKTX
$2.98B
| $9.81M | 0.5% |
370,000
+100,000
| +37% | +$2.65M |
|
53
HilleVax
HLVX
$105M
| $9.79M | 0.49% |
4,920,000
| – | – |
|
54
Vaxcyte
PCVX
$4.17B
| $9.75M | 0.49% |
300,000
| – | – |
|
55
Sanofi
SNY
$111B
| $9.66M | 0.49% |
200,000
-70,000
| -26% | -$3.38M |
|
56
GeneDx Holdings
WGS
$3.74B
| $9.23M | 0.47% |
+100,000
| New | +$9.23M |
|
57
AbCellera Biologics
ABCL
$1.24B
| $8.92M | 0.45% |
2,600,000
| – | – |
|
58
Harmony Biosciences
HRMY
$2.09B
| $8.89M | 0.45% |
281,200
| – | – |
|
59
Apogee Therapeutics
APGE
$2.21B
| $8.69M | 0.44% |
200,000
| – | – |
|
60
Idexx Laboratories
IDXX
$51.2B
| $8.58M | 0.43% |
16,000
+11,000
| +220% | +$5.9M |
|
61
Cullinan Oncology
CGEM
$408M
| $8.44M | 0.43% |
1,121,138
| – | – |
|
62
Moderna
MRNA
$9.45B
| $8.42M | 0.43% |
305,300
| – | – |
|
63
Alibaba
BABA
$312B
| $7.94M | 0.4% |
70,000
| – | – |
|
64
Eli Lilly
LLY
$666B
| $7.8M | 0.39% |
+10,000
| New | +$7.8M |
|
65
Nuvation Bio
NUVB
$1.17B
| $7.61M | 0.38% |
3,900,000
| – | – |
|
66
ESSA Pharma
EPIX
$11M
| $7.31M | 0.37% |
4,300,000
| – | – |
|
67
Sarepta Therapeutics
SRPT
$1.93B
| $7.19M | 0.36% |
+420,300
| New | +$7.19M |
|
68
BioCryst Pharmaceuticals
BCRX
$1.74B
| $7.17M | 0.36% |
800,000
| – | – |
|
69
Bausch + Lomb
BLCO
$5.16B
| $7.16M | 0.36% |
550,000
| – | – |
|
70
Pliant Therapeutics
PLRX
$100M
| $6.96M | 0.35% |
6,000,000
| – | – |
|
71
Ventyx Biosciences
VTYX
$185M
| $6.63M | 0.34% |
3,100,000
| – | – |
|
|
BIOA
72
BioAge Labs, Inc. Common Stock
BIOA
$169M
| $6.61M | 0.33% |
1,600,000
| – | – |
|
73
ImmunityBio
IBRX
$2.26B
| $6.16M | 0.31% |
2,333,333
| – | – |
|
74
Design Therapeutics
DSGN
$348M
| $6M | 0.3% |
1,780,975
+100,000
| +6% | +$337K |
|
|
ALMS
75
Alumis Inc. Common Stock
ALMS
$475M
| $5.99M | 0.3% |
+1,996,797
| New | +$5.99M |
|